Oncology Central

Merck & Co. to buy Viralytics to expand immuno-oncology pipeline

Merck & Co. have signed a definitive agreement to acquire Viralytics for approximately $394 million, the companies has announced.

Viralytics is an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers. Through the purchase, which is conditional on no better offer emerging from a counter-bidder, Merck will will be able to expand its drugs pipeline by gaining full rights to Cavatak®, Viralytics’ formulation of the oncolytic virus coxsackievirus Type A21.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.